| Literature DB >> 28474549 |
Da-Yong Lu1, Hong-Ying Wu2, Nagendra Sastry Yarla3, Bin Xu4, Jian Ding4, Ting-Ren Lu2.
Abstract
AIDS (acquired immune deficient syndrome) is a deadly human viral infectious disease caused by HIV (human immune-deficient virus) infection. Almost every AIDS patient losses his/her life before mid 1990s. AIDS was once the 1st disease killer in US (1993). After one decade hard work, antiviral drug cocktails-high active anti-retroviral therapy (HAART) have been invented for almost all HIV infection treatments. Due to the invention of HAART, 80-90% HIV/AIDS patients still effectively response to HAART for deadly AIDS episode controls and life saving. Yet, this type of HIV therapeutics is incurable. HIV/AIDS patients need to take HAART medications regularly and even life-long. To counteract this therapeutic drawback, more revolutionary efforts (different angles of therapeutic modes/attempts) are urgently needed. In this article, the major progresses and drawbacks of HIV/AIDS chemotherapy (HAART) to HIV/AIDS patients have been discussed. Future trends (updating pathogenesis study, next generations of drug developments, new drug target discovery, different scientific disciplinary and so on) are highlighted. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.Entities:
Keywords: HAART; HIV cure; HIV latency; HIV reservoirs; antiviral therapy; biotherapy; drug delivery system; integrase inhibitors; medicinal chemistry; pharmacogenomics
Mesh：
Substances：
Year: 2018 PMID： 28474549 DOI： 10.2174/1871526517666170505122800
Source DB: PubMed Journal: Infect Disord Drug Targets ISSN： 1871-5265